Literature DB >> 12913707

Leukocytes and bacteria in men with chronic prostatitis/chronic pelvic pain syndrome compared to asymptomatic controls.

J Curtis Nickel1, Richard B Alexander, Anthony J Schaeffer, J Richard Landis, Jill S Knauss, Kathleen J Propert.   

Abstract

PURPOSE: Chronic prostatitis has been traditionally characterized by inflammation and/or infection of the prostate gland, objectively categorized by white blood cells and cultured bacteria in prostate specific specimens. We compared leukocyte counts and localization rates for bacterial cultures of segmented urine samples (VB1, VB2, VB3), expressed prostatic secretion (EPS) and semen in men diagnosed with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) to men without pelvic pain (controls).
MATERIALS AND METHODS: A total of 463 men enrolled in the National Institutes of Health Chronic Prostatitis Cohort study and 121 age matched men without urinary symptoms had leukocyte counts performed and 5-day bacterial cultures on specimens obtained from a standard 4-glass test (VB1, VB2, EPS, VB3) and semen. All risk factor comparisons between case and control analyses were tested using generalized Mantel-Haenszel methods, and multivariable models were developed using logistic regression methods, adjusting for clustering by clinical center within both methods.
RESULTS: Men with CP/CPPS had statistically higher leukocyte counts in all segmented urine samples and EPS, but not in semen compared to asymptomatic control men. However, the control population also had a high prevalence of leukocytes. Of the men with CP/CPPS 50% and 32% had 5 or more, or 10 or more white blood cells (WBCs) per high power field, respectively, in EPS compared to 40% and 20% of the control population. Similarly, 32% and 14% of the patients with CP/CPPS had 5 or more, or 10 or more WBCs per high power field in VB3 compared to 19% and 11% in the control population. Localization of uropathogenic bacteria in EPS, VB3 and/or semen was similar in men with CP/CPPS (8.0%) and asymptomatic men (8.3%).
CONCLUSIONS: Men with CP/CPPS have significantly higher leukocyte counts in all segmented urine samples and EPS but not in semen as compared to controls. There is no difference in rates of localization of bacterial cultures for men with CP/CPPS compared to control men. The high prevalence of WBCs and positive bacterial cultures in the asymptomatic control population raises questions about the clinical usefulness of the standard 4-glass test as a diagnostic tool in men with CP/CPPS.

Entities:  

Mesh:

Year:  2003        PMID: 12913707     DOI: 10.1097/01.ju.0000082252.49374.e9

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  50 in total

1.  Uropathogenic Escherichia coli induces chronic pelvic pain.

Authors:  Charles N Rudick; Ruth E Berry; James R Johnson; Brian Johnston; David J Klumpp; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Prostate secretions from men with chronic pelvic pain syndrome inhibit proinflammatory mediators.

Authors:  Praveen Thumbikat; Shiva Shahrara; Rudina Sobkoviak; Joseph Done; Richard M Pope; Anthony J Schaeffer
Journal:  J Urol       Date:  2010-08-17       Impact factor: 7.450

Review 3.  Immune mediators of chronic pelvic pain syndrome.

Authors:  Stephen F Murphy; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Nat Rev Urol       Date:  2014-04-01       Impact factor: 14.432

4.  Overview of overactive bladder, prostatitis, and lower urinary tract symptoms for the primary care physician.

Authors:  Richard S Pelman
Journal:  Rev Urol       Date:  2004

5.  Identification of novel non-invasive biomarkers of urinary chronic pelvic pain syndrome: findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.

Authors:  Adelle Dagher; Adam Curatolo; Monisha Sachdev; Alisa J Stephens; Chris Mullins; J Richard Landis; Adrie van Bokhoven; Andrew El-Hayek; John W Froehlich; Andrew C Briscoe; Roopali Roy; Jiang Yang; Michel A Pontari; David Zurakowski; Richard S Lee; Marsha A Moses
Journal:  BJU Int       Date:  2017-04-11       Impact factor: 5.588

6.  Category III chronic prostatitis/chronic pelvic pain syndrome: insights from the National Institutes of Health Chronic Prostatitis Collaborative Research Network studies.

Authors:  J Curtis Nickel; Richard B Alexander; Rodney Anderson; Richard Berger; Craig V Comiter; Nand S Datta; Jackson E Fowler; John N Krieger; J Richard Landis; Mark S Litwin; Mary McNaughton-Collins; Michael P O'Leary; Michel A Pontari; Anthony J Schaeffer; Daniel A Shoskes; Paige White; John Kusek; Leroy Nyberg
Journal:  Curr Urol Rep       Date:  2008-07       Impact factor: 3.092

7.  Update on urologic pelvic pain syndromes: highlights from the 2010 international chronic pelvic pain symposium and workshop, august 29, 2010, kingston, ontario, Canada.

Authors:  J Curtis Nickel; Dean Tripp; Allan Gordon; Michel Pontari; Daniel Shoskes; Kenneth M Peters; Ragi Doggweiler; Andrew Paul Baranowski
Journal:  Rev Urol       Date:  2011

8.  Excessive antibiotic use in men with prostatitis.

Authors:  Brent C Taylor; Siamak Noorbaloochi; Mary McNaughton-Collins; Christopher S Saigal; Min-Woong Sohn; Michel A Pontari; Mark S Litwin; Timothy J Wilt
Journal:  Am J Med       Date:  2008-05       Impact factor: 4.965

Review 9.  Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy.

Authors:  A S Polackwich; D A Shoskes
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-08       Impact factor: 5.554

Review 10.  Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment.

Authors:  Michel A Pontari
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.